NEW YORK, December 28, 2016 /PRNewswire/ --
Ahead of today's session, Stock-Callers.com presents these four equities in the Medical Appliances and Equipment space for review: Lantheus Holdings Inc. (NASDAQ: LNTH), Nevro Corp. (NYSE: NVRO), Steris PLC (NYSE: STE), and The Spectranetics Corp. (NASDAQ: SPNC). These firms belong to the Healthcare sector which was moderately higher on Tuesday, December 27th, 2016. As per a NASDAQ report, the NYSE Health Care Index climbed about 0.2%, while shares of health care companies in the S&P 500 rose about 0.2% as a group. Learn more about these stocks by downloading their free report at:
On Tuesday, shares in North Billerica, Massachusetts headquartered Lantheus Holdings Inc. recorded a trading volume of 135,269 shares. The stock ended the session 1.17% lower at $8.45. The Company's shares have gained 2.80% in the previous three months and 150.00% since the start of this year. The stock is trading 50.19% above its 200-day moving average. Moreover, shares of Lantheus Holdings, which develops, manufactures, and commercializes diagnostic medical imaging agents and products for the diagnosis and treatment of cardiovascular and other diseases worldwide, have a Relative Strength Index (RSI) of 40.66.
As per a SEC filing dated November 17th, 2016, Lantheus Holdings entered into an underwriting agreement on November 15th, 2016, with the selling stockholders listed on Schedule II thereto, and Credit Suisse Securities LLC, as the underwriter relating to the underwritten offering of 3,500,000 shares of its common stock, par value $0.01 per share, including 1,000,000 shares to be sold by the company and 2,500,000 shares to be sold by the selling stockholders. The free research report on LNTH is available at:
Redwood City, California headquartered Nevro Corp.'s stock closed the day 0.58% higher at $71.39 with a total trading volume of 215,986 shares. The Company's shares have advanced 5.75% on an YTD basis. The stock is trading 10.46% below its 200-day moving average. Additionally, shares of Nevro, which develops and commercializes a neuromodulation platform for the treatment of chronic pain in the US, Europe, and Australia, have an RSI of 33.19.
As per a SEC filing dated December 20th, 2016, Nevro Corp., on December 19th, 2016, entered into a First Amendment to Lease with Westport Office Park, LLC effective as of December 9th, 2016. Pursuant to the Lease Amendment, the Company will lease an additional approximately 49,980 square feet of office space adjacent to the Original Premises at 1600 Bridge Parkway, Redwood City, California 94065 for expansion of the Company's principal executive offices. The complimentary report on NVRO can be downloaded at:
Shares in Leicester, the UK headquartered Steris PLC recorded a trading volume of 294,404 shares, and ended yesterday's trading session 0.32% lower at $68.87. The Company's shares have advanced 2.67% in the past month. The stock is trading above its 50-day moving average by 2.69%. Furthermore, shares of Steris, which develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and surgical and gastrointestinal support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental customers worldwide, have an RSI of 58.17.
On November 2nd, 2016, STERIS announced that Q2 FY17 revenue increased 32% to $646.4 million compared to $489.9 million in Q2 FY16. The Company's reported net income for Q2 FY17 was $40.4 million, or $0.47 per diluted share, compared to net income of $8.7 million, or $0.14 per diluted share, in Q2 FY16.
On November 30th, 2016, research firm Goldman initiated a 'Neutral' rating on the Company's stock, with a target price of $71 per share. Visit us today and download our complete research report on STE for free at:
Colorado Springs, Colorado headquartered The Spectranetics Corp.'s stock finished Tuesday's session 1.01% higher at $25.00 with a total trading volume of 357,345 shares. The Company's shares have advanced 7.30% in the last one month, 3.39% over the previous three months, and 66.00% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 7.53% and 19.31%, respectively. Additionally, shares of Spectranetics, which together with its subsidiaries, develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures in the cardiovascular system, have an RSI of 63.19.
On November 21st, 2016, Spectranetics announced that its Stellarex™ 0.014" Drug-coated Angioplasty Balloon (DCB) has received the CE mark. The Stellarex 0.014" device is designed to treat small vessels, below-the-knee disease, and challenging critical limb ischemia in patients. The combination of the currently available Stellarex 0.035" and the new 0.014" line available in Europe expands Spectranetics' comprehensive portfolio of next generation DCBs to treat complex disease states across the lower extremities.
On December 16th, 2016, research firm Raymond James initiated an 'Outperform' rating on the Company's stock. Get free access to your technical report on SPNC at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA